Amolyt Pharma

Our goal is to provide physicians with new therapeutic strategies to improve the lives of their patients with rare endocrine and related diseases. We are supported by an impressive board of directors and strong international syndicate of investors, as well as a robust IP portfolio and key academic collaborations. Thierry Abribat is a biotech entrepreneur who has founded and managed three biotech companies, one of which, Alizé Pharma 2, was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) and, another, Alizé Pharma, was acquired by Millendo Therapeutics (Nasdaq: MLND). Mark Sumeray has 23 years of experience across the pharmaceutical, medical devices and biotech industries, both in the US and EU. Thomas Delale is a biopharmaceutical professional with over 18 years of experience that spans from peptide drug discovery to late clinical stage development and corporate/business development. David has a strong experience working with CMO/CRO and developing product with top pharmaceutical or biotechnologies companies in Europe, US, India and China. Benedicte Gagnere has over 20 years experience in leading financial planning, control & accounting functions and reporting on all international operations. Legault also serves as the chairman of Artios Pharma, Bicycle Therapeutics and Poxel Pharma.